Finanzen von BioRestorative Therapies Inc (BRTX)BRTXBioRestorative Therapies Inc

Evaluating the bottom line, BioRestorative Therapies Inc maintains a gross margin of 68.13%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -14612.57%, while the net margin is -9298.25%. These profitability ratios, combined with a Return on Equity (ROE) of -241.50%, provide a clear picture of how effectively BRTX converts its operational activities into shareholder value.

In the context of the broader market, BRTX competes directly with industry leaders such as ICCM and ADGM. With a market capitalization of $2.06M, it holds a significant position in the sector. When comparing efficiency, BRTX's gross margin of 68.13% stands against ICCM's 27.89% and ADGM's N/A. Such benchmarking helps identify whether BioRestorative Therapies Inc is trading at a premium or discount relative to its financial performance.

The gross margin for the latest quarter is 68.13%, which is relatively strong, but the company has been consistently reporting negative net income, with the latest net income at -2,154,405 USD. This indicates ongoing financial challenges despite some revenue growth.